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Hepatitis B virus variants harboring nucleotide alterations in the preC-C promoter have been detected in fulminant hepatitis
B as well as in HBeAg-seronegative persistent infection. However, it has not been demonstrated that variants with nucleotide
alterations in the preC-C promoter cause various disease states. We replaced the preC-C promoter region of a wild-type
genome with the most frequent naturally occurring mutated form and introduced it into HepG2 cells. The mutant with
coexisting A1762T and G1764A substitutions produced less than one-fifth of the wild-type level of HBeAg. Conversely, the
mutant generated 2.4 times more core particle antigen and showed a high-replicator phenotype. RNase protection and
quantitative 5* RACE showed a 16- to 32-fold reduction of preC transcripts and a 4-fold induction of C transcripts of the
mutant compared to wild-type. The preC transcript of the mutant had a more heterogeneous 5* end than that of the wild-
type. However, the mutations did not alter the initiation sites of C transcription. When the promoter region was cloned into
CAT plasmids, the mutations had dual effects on preC and C promoter activities, decreasing and increasing them, respec-
tively. These results suggest that these mutations are responsible for the reduced HBeAg production as well as the enhanced
replication and core production. Analysis of revertants with either single point mutation showed that T at 1762 is critical
for the mutant phenotype. q 1996 Academic Press, Inc.
INTRODUCTION sis of nucleotide sequence data for the HBV genome
suggests that nonsense mutations within the preC open
The hepatitis B virus (HBV) e antigen (HBeAg) precur- reading frame (ORF) (Brunetto et al., 1989; Carman et al.,
sor is translated from over-genome length 3.5-kb tran- 1989; Okamoto et al., 1990; Kosaka et al., 1991; Omata
scripts, which initiate 22 to 28 bp upstream from the et al., 1991; Liang et al., 1991) as well as nucleotide
precore (preC) initiation codon (Yaginuma and Koike, substitutions, insertions, and deletions in the preC-C pro-
1989; Chen et al., 1993). The 214 amino acid (aa) long moter region (Feitelson et al., 1991; Kim et al., 1992; Repp
precursor (212 aa in several subtypes carrying a 6-bp et al., 1992; Preisler-Adams et al., 1993; Laskus et al.,
shorter C gene) loses the amino-terminal 19 aa, con- 1994; Moriyama et al., 1994; Horikita et al., 1994; Oka-
taining the signal sequence, after the protein translo- moto et al., 1994; Sato et al., 1995) might be factors de-
cates cotranslationally into the endoplasmic reticulum. termining the HBeAg-negative phenotype and the sever-
This processed protein then loses 36 (or 34) aa from ity of hepatitis. In the preC-C promoter mutants, altered
the carboxyl-terminal in the Golgi apparatus (Bruss and residues are usually between positions 1753 and 1772,
Gerlich, 1988; Jean-Jean et al., 1989). The secreted 159- the most common alterations being two coexisting point
aa HBeAg circulates in association with plasma proteins mutations, A to T at 1762 (A1762T) and G to A at 1764
(Machida et al., 1991). Although the secretion pathway (G1764A) (Okamoto et al., 1994). These mutations would
that produces circulating HBeAg has been elucidated in directly affect the functions of the overlapping X gene
detail, little is known about HBeAg’s biological functions.
product. Also, they may affect the enhancer II element,
HBV carriers with serum HBeAg generally show high
since several proteins bind to the region encompassing
levels of virus and higher rates of transmission (Alter et
these mutations.
al., 1976; Okada et al., 1976; Werner et al., 1977). On the
Since preC nonsense mutations abort the synthesis ofother hand, fulminant hepatitis B can occur as a primary
HBeAg, seroconversion from HBeAg positive to anti-HBeinfection of the virus which has been harbored in an
positive is believed to be induced by the immune pres-HBeAg-negative HBV carrier (Fagan et al., 1986). Analy-
sure of the host against wild-type (wt) HBV toward pre-
dominance of HBeAg-negative mutants. Thus, viruses
possessing only mutations within the promoter region1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 212-860-3369. E-mail: moriyama@MSVAX.MSSM.EDU. could produce phenotypes analogous to those of preC
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ORF mutants. Moreover, such promoter mutants with an (PCR)-based site-directed mutagenesis (Landt et al., 1990)
of pYWAG, which was derived from a plasmid pPYW310intact preC ORF have been found in HBV carriers nega-
tive for both HBeAg and anti-HBe (Moriyama et al., 1994; (a pUC119 having at the PstI site a 3182-bp complete HBV
genome, subtype ayw and genotype D, which had beenOkamoto et al., 1994). Although these cases are consis-
tent with preC-C promoter mutations being responsible cloned from the serum of an HBeAg-positive carrier (Oka-
moto et al., 1990)). The two first-step PCRs were performedfor the defective production of HBeAg, this has yet to be
experimentally proven. with forward primer B026, 5*GACAACTCTGTTGTCCTC-
TCC, and mutagenized reverse primers, and reverseThe sequence patterns of the preC-C promoter muta-
tions found in Japanese patients with fulminant or severe primer B046, 5*TGCTCAGGAGACTCTAAGGC, and muta-
genized forward primers. Mutagenized oligonucleotideshepatitis B (Sato et al., 1995) resemble those observed
in HBeAg-negative persistence (Okamoto et al., 1994). were B047, 5*AGGTTAATGATCTTTGTACTAG, and B048,
5*CTAGTACAAAGATCATTAACCT, for pYWTA (1762 A toHowever, it has not been determined if these promoter
mutations played a causal role in the severity of the T, 1764 G to A), B071, 5*GATTAGGTTAATGGTCTTTG-
TAC, and B072, 5*CAAAGACCATTAACCTAATCTCCT, fordisease. Some investigators have proposed that the ful-
minant phenotype is not solely attributable to preC trans- pYWTG (1762 A to T), B073, 5*ATTAGGTTAAAGATCTTTG-
TACTA, and B074, 5*ACAAAGATCTTTAACCTAATCTCCT,lational termination (Ogata et al., 1993; Hasegawa et al.,
1994), based on intensive in vitro analysis, and experi- for pYWAA (1764 G to A) and B064, 5*TGGGTGGCTTTA-
GGGCATGGAC, and B065, 5*ATGTCCATGCCCTAAAGCC-mental infection of chimpanzees, using clinical sample
HBV harboring both the preC-C promoter and preC ORF ACCCA, for pYWPCTer. Second PCR products using prim-
ers B026 and B046 encompassed positions 1333 to 2040mutations along with several sequence variations in
other regions. of HBV. Both ends of the 1.1-kb fragments were digested
with NcoI and SacII and replaced with the wt NcoI–SacIIThe C gene product, HBcAg, is translated from another
3.5-kb transcript, of which the 5* end is 29 to 35 nucleo- fragment of pPYW310. The replication-competent homoge-
neous tandem dimer of the 6.4-kb HBV genome wastides shorter than that of the preC mRNA, and in which
the preC initiation codon is absent. This transcript also cloned at the unique PstI site of pUC119 and designated
p2WAG (from pYWAG), p2WTA (pYWTA), p2WTG (pYWTG),serves as the mRNA for the DNA polymerase-reverse
transcriptase (pol) and as the pregenome (Seeger et al., or p2WAA (pYWAA) (Fig. 1). The relative orientation of the
viral DNA and vector DNA was identical for the dimer1986; Will et al., 1987; Enders et al., 1987; Nassal et al.,
1990), which is the template for the reverse transcription constructs. p2WAG and p2WTA were cleaved at the unique
SphI site at position 1233, and the monomeric replication-of pol (Ou et al., 1990). C gene transcription is controlled
by the upstream regulatory element and the basic C pro- incompetent 3.2-kb HBV DNA was cloned at the SphI site
of pUC19 and designated pSpAG (from p2WAG) or pSpTAmoter (position from 1643 to 1849) and negative regula-
tory element (1611 to 1634) (Honigwachs et al., 1989; Lo (from p2WTA). Plasmid DC has a tandem dimer with 2-bp
deletion at positions 2003 and 2004 in the C ORF (Okamotoand Ting, 1994). However, the role of this promoter region
in transcription of the overlapping preC has not been et al., 1990). This frame shift mutation alters C peptide aa
sequence from 35 and prematurely terminates its transla-closely examined.
Another interesting finding among the promoter mu- tion at 45.
To construct pBasic.d5*CAT, in which 38-bp was de-tants is that a one-point mutation has not been found in
any variants, even some quasi-species consist of such a leted from the 5* untranslated region (UTR) of the chlor-
amphenicol acetyl transferase (CAT) gene of pCAT-Basictwo-point mutation clone and a wt clone. Why are multiply
substituted mutants selected or replicatively superior to (Promega), part of the CAT ORF encompassing the region
from the initiation codon to a unique NcoI site was ampli-the presumptive single-substituted mutants. Is a single-
substituted residue responsible for the HBeAg-seronega- fied by PCR using primers B077, 5*GACTCTAGACTA-
AAATGGAGAAAAAAATCA, and B078, 5*CAGCACCTT-tivity and another for the severity of the disease.
In this study, we demonstrated that the A1762T, GTCGCCTTGCG, and ligated with the larger fragment of
XbaI and NcoI-digested pCAT-Basic DNA. For pAG.d5*-G1764A double mutation is responsible for defective pro-
duction of HBeAg at the transcriptional level and for en- CAT, pTA.d5*CAT, pTG.d5*CAT, and pAA.d5*CAT, a DNA
fragment from position 1630 to 1799 of each wt or muta-hanced HBcAg production and replication. Moreover, we
attempted to resolve the reason of the coexistence of genized HBV DNA was amplified by PCR using primers
B067, 5*GGAGTCGACCAAATCTTGCCCAAGGTCT, andthe two nucleotide changes in one clone by analyzing
the single-substituted revertants. B068, 5*TGCGTCGACCAATTTATGCCTACAGCC, both of
which contain a created Sal I site, and cloned into the
MATERIALS AND METHODS
Sal I site of the pBasic.d5*CAT (Fig. 5A). For pAG.79.CAT,
Plasmids pTA.79.CAT, pTG.79.CAT, and pAA.79.CAT, each HBV
DNA between positions 1630 and 1846 was amplifiedPlasmids carrying an HBV DNA with preC-C promoter
mutations were produced by polymerase chain reaction with primers B067 and B079, 5*CAGATCTAGAGATGAT-
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TAGGCAGAGGTG, digested with Sal I and XbaI, and then TBST, the membrane was incubated with horseradish
peroxidase-labeled anti-mouse immunoglobulin antibod-cloned into the Sal I– XbaI-digest of the pCAT-Basic
vector. ies and then examined using a chemical luminescence
system (Amersham).
Transfection and ELISA of HBV antigens and hGH
Southern blotting
HepG2 cells (Aden et al., 1979) were cultured in 60-
mm dishes containing DMEM supplemented with 10% To isolate encapsidated viral DNA, 4 ml of culture me-
dium was centrifuged at 273,000 g for 3 hr. The pelletcalf serum (CS). Recombinant plasmids were introduced
into the cells using polycationic lipids (LipofectAMINE, was suspended in 1 ml PBS, overlaid on 3.5 ml of 20%
sucrose-PBS, and centrifuged 273,000 g for 3 hr. TheGibco). For triplicate transfection, 15.0 mg of plasmid car-
rying HBV genomes and 3.0 mg of pTKGH (Selden et al., resulting pellet was suspended in 1 ml of 10 mM Tris–
HCl, pH 8.8, 5 mM CaCl2 , and 1 U/ml staphylococcal1986) were mixed with 90 ml of the lipid solution in 1200
ml of reduced serum medium (Gibco), and the mixture nuclease (Sigma). The reaction mixture was diluted to
0.5% (wt/vol) in SDS and 0.2 mg/ml in proteinase K andwas incubated at 227 for 30 min then diluted with 4.8 ml of
the reduced serum medium. Two milliliters of this diluted further incubated at 557 for 2 hr. DNA was extracted with
phenol and chloroform and precipitated with ethanol. Themixture per dish was overlaid on the cells. After 6 hr of
incubation at 377, 2.0 ml of DMEM containing 20% CS DNA was then completely digested with DpnI, subjected
to electrophoresis in 1.0% agarose gel, and blotted ontowas added, and the dishes were further incubated for
12 hr. Then the culture medium was replaced with 4 ml a nylon filter membrane. Hybridization was carried out
with PCR-amplified HBV DNA (spanning positions 747–of fresh DMEM containing 10% CS.
For ELISA of the cell lysates for HBV antigens, cells 1823 and 2413–3182/1–197 of pPYW310) labeled with
[a32P]dCTP, and the filters were washed under highlywere rinsed 3 times with 5 ml of phosphate-buffered saline
(PBS), scraped into 1 ml of PBS, and collected in the stringent conditions. Radioactivity of specific bands was
counted with a BAS 2000 image analyzer (Fuji Film,bottom of a sample tube by brief centrifugation. The cell
pellet was suspended in 200 ml of 0.25 M Tris–HCl, pH Tokyo).
7.5, and stored at 0707. For ELISA, an equal volume of
Ribonuclease protection assay and 5* anchored RACE21 lysis solution consisting of 150 mM NaCl, 20 mM
EDTA, pH 8.0, and 1 mM PMSF (Sigma) was added to the
Cells in a 60-mm dish were harvested 48 hr after trans-
suspension, and then the mixture was vortexed for 15 sec
fection with either p2WAG or p2WTA. Total RNA was
and centrifuged at 12,000 g for 3 min. Part of the superna-
isolated as described previously (Edwards et al., 1991),
tant was then diluted to an adequate concentration to fit
treated extensively with DNase1, and poly(A) RNA was
within the linear range of light absorbance. HBsAg was
isolated using an oligo-dT cellulose column. For the ribo-
tested using anti-HBs horse serum as an immobilized
probe, the HBV sequence between the Sau3AI site at
antibody and sandwiched with a monoclonal antibody
1762 and the StyI site at 1883 of pYWTA was excised
(mAb) against the common determinants of HBsAg (No.
and cloned into the BamHI site of pBluescriptKS/ (Stra-
824) (Usuda et al., 1986). Hepatitis B nucleocapsid antigen
tagene). The resulting clone, pKSuSy, bearing one copy
(HBcAg), representing viral C particles, was determined
of the insert oriented so that the Bgl II end ligates to the
by sandwiching it between two mAbs of distinct specificity
T3 promoter side, was used. The unique XbaI site of
(Nos. 3120 and 3105) (Takahashi et al., 1983). Similarly,
pKSuSy, which exists between the T7 promoter and the
HBeAg was determined by sandwiching it between two
Sau3AI end of the cloned fragment, was cleaved, and
mAbs (Nos. 904 and 905) (Imai et al., 1982). The amount
an RNA probe was synthesized in vitro using T3 RNA
of human growth hormone (hGH) in the culture superna-
polymerase in the presence of [32P]rCTP. Two micro-
tant was determined with an hGH ELISA kit (Boehringer–
grams of total RNA or 0.5 mg mRNA of each transfected
Mannheim) and substrate OPD (Sigma).
monolayer culture was hybridized with riboprobe in molar
excess (Herbomel et al., 1984). After digestion withSDS–PAGE and immunodetection
RNase A and T1 (Boehringer Mannheim), the protected
RNA was electrophoresed in a 15% acrylamide gel.For detection of HBeAg and C peptides, 5 ml of culture
medium or cell lysate was mixed with an equal volume The quantities and 5* ends of both the preC and C
mRNA were also determined by 5* anchored rapid ampli-of 21 gel-loading buffer and a total of 10 ml was sub-
jected to SDS–PAGE, followed by transfer to a nitrocellu- fication of cDNA ends (RACE) of polyadenylated RNA.
cDNA was synthesized with primer B046 using reverselose filter membrane. The membrane was immersed in
Tris-buffered saline (TBST) (10 mM Tris–HCl, pH 7.5, 0.15 transcriptase (Superscript II, Gibco) and appended
buffer. After removal of RNA by adding a 1/10 vol of 2 NM NaCl, 0.1% (vol/vol) Tween-20) containing 5% skim milk
and incubated at 227 for 60 min with primary mAb (No. NaOH and incubation at 507 for 30 min, excess primers
and dNTP were removed by passage through an agarose2221) (Machida et al., 1991). After being washed with
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FIG. 1. Schematic diagram (A), nucleotide sequence of the mutated HBV DNA (B), and deduced amino acid substitutions of HBx (C). (A) The
basic core promoter (BCP) and core upstream regulatory sequence (CURS) (Yuh et al., 1992), liver-specific enhancer II (EnhII) (Wang et al., 1990,
Yee, 1989), negative regulatory element (NRE) (Lo and Ting, 1994), DR1, DR2, and the pregenome encapsidation signal (e) (Junker-Niepmann et al.,
1990) are presented. (B) The sequence of wt HBV DNA contained in p2WAG is indicated at the top. AT-rich regions are indicated by underlines.
The previously reported transcription initiation sites for preC and C mRNAs, start codons for preC and C, are indicated. Three created mutations
are listed below. Dashes represent nucleotides identical to those of p2WAG. All plasmids harbor a homogeneous tandem dimeric HBV genome
connected with pUC119 at the unique PstI site at position 515 of HBV. (C) Dashes represent amino acids identical to those of p2WAG.
column (Chromaspin-100, Funakoshi, Tokyo) and the pTKGH with polycationic lipids. Six days after transfection,
the cells were harvested and their extract was preparedcDNA was ligated with 5* phosphorylated and 3* ami-
nated 46-mer anchor deoxyoligonucleotide B100, 5* PO4- as described above. CAT polypeptide was quantified with
a CAT-ELISA kit (Boehringer–Mannheim) and OPD. For 5*GCACTTGACTAGGATCCACTGAATTCTTTAGTGAGG-
GTTAATTGCC-NH3 , using T4 RNA ligase (Takara, Shiga, RACE of CAT mRNA, cDNA was synthesized using a
primer B078, CAGCACCTTGTCGCCTTGCG, as describedJapan). After a 24-hr ligation reaction in 10 ml of reaction
mixture at 167, half of the mixture was used for the first above. The PCR was performed using primers BUPC,
5*AAGGCCGTAATATCCAGC, and B101.PCR with primers B101, 5*GGCAATTAACCCCTCACT-
AAAG, and B102, 5*GCCACCCCAAGGCACAGCTTG,
which anneal with the anchor and cDNA, respectively. RESULTS
The nested PCR was performed using primers B103,
Antigen production and replication of the preC-C5*AAAGAATTCAGTGGATCCTAG, and B104, 5*ACA-
promoter mutantGAATTCAGCTTGGAGGCTTGAACAGT. The EcoRI- and
BamHI-digested PCR product was cloned into pUC19, and
We set out to clarify how the previously reported nucle-the 3* end of the cDNA was determined by sequencing.
otide substitutions in the preC-C promoter are associated
CAT-ELISA and 5* RACE with the HBeAg-seronegative phenotype and fulminant
hepatitis B. We first constructed a homogeneous tandemFor CAT-ELISA, HepG2 cells in a 60-mm dish were
transfected with 5 mg of CAT plasmid along with 1 mg of dimer of the entire HBV genome containing the preC-C
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TABLE 1
HBV Antigen Titers in Cell Extracts and Culture Medium of HepG2 Cells Transfected with HBV Genome with a wt (p2WAG, pSpAG) or a
Mutated preC-C Promoter (p2WTA, pSpTA)
hGH (medium) HBsAg (medium) HBcAg (cell) HBeAg (medium)
Dimer
p2WAG 742a 1,531a (221 { 36)b 521a (75 { 8) 844a (118 { 6)
p2WTA 615 781 (134 { 16) 1,059 (188 { 31) 340 (55 { 7)
DC 738 1,640 (235 { 22) 10 34
Mock 52 35 10 32
Monomer
pSpAG 960 299 (29 { 2) 522 (53 { 6) 344 (35 { 3)
pSpTA 925 185 (17 { 2) 1,127 (124 { 8) 147 (14 { 2)
Mock 45 34 39 24
a Average light absorbance (A492 1 1000) in ELISA of triplicate cultures.
b Light absorbance for each antigen was converted to an absolute unit using the standard curve, divided by the absolute unit for each hGH, and
the average and 1 SD of the resulting triplicate relative units are shown in parentheses. Plasmid DC has a tandem dimer with a 2-bp deletion at
positions 2003 and 2004 in the C ORF (Okamoto et al., 1990) and was used as a negative control plasmid for HBcAg and HBeAg.
promoter substitutions. p2WTA harbors the most com- both cases began to decrease at 48 hr. The rise and fall
of HBeAg showed similar time courses for both p2WTAmon preC-C promoter mutation, A1762T and G1764A (de-
duced HBx aa substitutions Lys130Met and Val131Ile). and p2WAG (Fig. 3). HBeAg production was followed by
long-term culture with changes of medium every 3 days;We then compared the properties of HepG2 cells trans-
fected with p2WTA vs wt, p2WAG (Fig. 1). p2WTA re- the HBeAg production was restored by replacing the cul-
ture medium. However, maximum HBeAg titers at 48 hrleased HBeAg into the culture medium at a level detect-
able by ELISA. However, the quantity of released antigen were reduced by every change of medium, and by the
third change the minimum ratio of HBeAg titer for p2WTA72 hr after transfection was reduced to 40% of the level
of p2WAG-transfected cells (Table 1). HBsAg titer was reached only one-fifth that of p2WAG (Fig. 3).
60% that of p2WAG-transfected cells. Moreover, the mu-
tant induced 2.4 times the amount of HBcAg in the HepG2 Quantitation and mapping of preC and C transcripts
cells in comparison to p2WAG-transfected cells. Similar
changes in the antigen titers were observed with the RNase protection assays (RPAs) with mRNA from
transfected cells showed that there was more C tran-replication-defective HBV-DNA monomers (Table 1).
Western blots of the culture medium showed that the script in cells transfected with p2WTA than that in cells
transfected with p2WAG (Fig. 4B).intensity of the p17e bands tightly correlated with the
HBeAg ELISA titer (Fig. 2A). Neither C particle-specific The protected product from common ends obscured
the preC mRNA band. Thus, we performed semiquantita-antigenicity nor a p21c band was detected in any culture
medium by ELISA (data not shown) or Western blotting, tive anchored 5* RACE. Agarose gel electrophoresis of
RACE products showed markedly (16- to 32-fold) reducedrespectively. Thus, only the secretory form of HBeAg
(p17e), and not the HBeAg precursors or degraded forms preC transcripts as well as 4- to 8-fold inductions of
C transcripts of p2WTA (Fig. 4C). Similar results wereof C peptide polymer which harbor cryptic HBe-antigenic-
ity, were quantified by ELISA of the culture medium. obtained with oligo-dT-purified mRNA (not shown). Se-
quencing of the RACE products showed altered tran-Western blots of the cell extracts showed a 21-kDa band
(Fig. 2A), confirming the high HBcAg titer. scriptional initiation points for the p2WTA preC mRNA,
scattered between 1759 and 1797. However, the initiationWe have demonstrated in vitro the HBeAg-reduced
phenotype of the promoter mutant, as had been predicted site of the C mRNA was the same for p2WTA and p2WAG
(Fig. 4D).based on clinical observations. Moreover, we found
herein the enhanced C particle production of the mutant. We quantified both preC and C promoter activities us-
ing the CAT gene as a reporter, so that the altered over-Southern blots of progeny virus DNA in the culture
medium showed that cells transfected with p2WTA re- lapping X gene products and preC-mediated inhibition
(Lamberts et al., 1993) would not be involved. pAG.d5*-leased three times more encapsidated virus DNA than
those transfected with the p2WAG (Fig. 2B). CAT and its derivative harbor either a wt or a mutated
170-bp fragment from positions 1630 to 1799. The in-We plotted the HBeAg and HBsAg titers of the culture
medium every 12 hr after transfection. The cells trans- serted region contains the third AT-rich region that can
serve as the initiator for the preC transcripts when clonedfected with either p2WAG or p2WTA produced HBsAg at
a constant rate up to 72 hr, whereas the HBeAg titers in downstream from a heterogeneous enhancer (Chen et
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FIG. 2. Western blots of preC and C polypeptides produced by cells transfected with the tandem dimers of HBV DNA (A) and Southern blot
hybridization of HBV DNA extracted from viral particles in culture medium of HepG2 cells 4 days after transfection (B). (A) Culture medium and cell
extracts, whose antigen titers are shown in Table 1. p2WPCTer carries a dimeric HBV DNA harboring a nonsense mutation in the preC region
(G1896A). e, affinity-purified HBeAg from pooled carrier serum. c, affinity-purified HBcAg produced by an integrated HBV DNA in hepatoma tissue
transplanted subcutaneously into nude mice (Matsui et al., 1986). (B) The background count was subtracted from total radioactivity for each HBV-
specific bands and the result shown at the bottom. M, 5.8, 3.2, and 1.1 kb of linear plasmid molecules of HBV DNA, as molecular markers. The
migration positions of relaxed circular (RC), linear (L), and single-stranded (SS) DNA are indicated. M.O., HBV DNA isolated from a serum pool of
HBeAg-positive carriers.
al., 1995). The fragment was inserted 14-bp upstream of determined why such mutants are selected or if they
the CAT initiation codon, and only transcripts that are have a replicative advantage over the hypothetical sin-
initiated upstream from the CAT initiation codon (preC gle-point mutants. Nor has it been determined if one of
initiation codon equivalent) can be translated. Thus the the substituted residues is responsible for decreased
p.d5*CAT series tests preC promoter activities (Fig. 5A). HBeAg production and another for increased HBcAg pro-
When transfected into HepG2 cells, pTA.d5*CAT, harbor- duction. We constructed revertant plasmids harboring
ing the TA mutation, produced 20% of the CAT antigen the mutated HBV genome with either A1762T (p2WTG) or
produced by pAG.d5*CAT (Fig. 5B). G1764A (p2WAA), and compared their phenotypes with
The p.79.CAT series carries a mutated 216-bp frag- those of the wt (p2WAG) and the double mutant (p2WTA).
ment from position 1630 to 1846 (Fig. 5A). The inserted Compared to wt p2WAG, p2WTG-transfected HepG2
promoter fragments contain the preC initiation codon, cells produced lower HBsAg and HBeAg and abundant
but this reading frame terminates at the TAA codon 13 HBcAg. Whereas, p2WAA produced lower amounts of
bp upstream from the CAT initiation codon. Thus, the HBsAg but the same amount of HBeAg as the wt trans-
CAT antigen titer should reflect only the C transcript fected cells (Table 2). When the replication capacity of
equivalents, which start downstream from the 1814 preC these four HBV types were compared by the Southern
initiation codon. Consequently, pTA.79.CAT produced blots, all tandem dimers with either mutation were repli-
twofold more CAT than the wt pAG.79.CAT (Fig. 5C). cation-competent, but p2WTA and p2WTG released their
A semiquantitative 5* RACE of CAT mRNA of pAG.79.- progeny more than the others (Fig. 6).
CAT and pTA.79.CAT showed 10- to 50-fold reduced preC When we compared the preC promoter activities of the
transcription and 4- to 16-fold enhanced C transcription A1762T- and G1764A-mutants using p.d5*CAT plasmids,
from the mutant promoter (Fig. 5D). the A1762T-mutant (pTG.d5*CAT) showed its preC-pro-
Therefore, the mutation alters the initiation sites and
moter activity to be stronger than the wt (pAG.d5*CAT),
reduces the amount of preC mRNA generated. Also, it
just like the double-mutant (pTA.d5*CAT) (Fig. 5B). The
increases C mRNA generation without altering the initia-
G1764A-mutant (pAA.d5*CAT) showed similar activity
tion site.
of preC promoters as with wt, as indicated by the anti-
genic phenotype of tandem dimers of genome-length
Phenotypic analysis of singly substituted mutants
HBV DNA.
Our examination of the p.79.CAT series showed thatMost of the reported preC-C promoter mutants carry
two or more nucleotide substitutions. It has not been the promoter with the A1762T-mutation (pTG.79.CAT)
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FIG. 3. Time courses of HBsAg and HBeAg titers in the culture medium of cells transfected with p2WAG or p2WTA. First, second, third, and
fourth medium replacements were performed 1, 4, 7, and 10 days after transfection, respectively. Each 150 ml of the medium was collected every
12 hr after the second medium change. Optical density within a linear range of the sandwich-ELISA for serially diluted samples was used. The
mean titers of triplicate cultures were converted to arbitrary units using a standard curve and an hGH titer, as described in Table 1. Error bars
indicate 1 SD for each triplicate culture.
displayed the same activity as that with the double- between in vivo infection and in vitro transfection. In in-
fections with the preC-C promoter mutants, HBeAg mightmutation (pTA.79.CAT), whereas that with the G1764A-
mutation (pAA.79.CAT) showed the same activity as the be produced and then cleared to reach a level undetect-
able in serological tests, even in individuals without anywt (pAG.79.CAT) (Fig. 5C).
The 5* RACE of CAT mRNA of pTG.79.CAT and detectable anti-HBe antibodies. In our in vitro time
courses, HBeAg levels of both wt and mutant HBV mark-pAA.79.CAT confirmed the reduced preC transcription
and enhanced C transcription of the mutant promoter edly decreased in unchanged culture medium between
every medium changes (Fig. 3). The fresh medium might(Fig. 5D).
Therefore, A1762T is essential and sufficient for the contain some factors that causes the cells to produce
HBeAg or that binds to HBeAg to protect it from degrada-mutant phenotype demonstrated by the double mutant.
tion.
We demonstrated that the A1762T, G1764A double mu-DISCUSSION
tation directly alters both the preC and C promoter activi-
ties decreasing and increasing, respectively. The doubleLow level production of HBeAg by HBV DNA with the
mutation also altered the initiation sites of the reducedpreC-C promoter mutations found in patients with
level transcripts. However, the mutations did not shiftHBeAg-negative persistent infections was demonstrated
the initiation site of C transcript; alterations of this siteby transfection of cultured cells. However, complete ab-
determine the length of 5* UTR and affect the efficiencysence of HBeAg production could not be demonstrated
of translation (Weimer et al., 1987). It appears that thewith this system; one-fifth that of the wt was found. The
leaky HBeAg production might be due to the difference third AT-rich region did not work as an initiator of preC
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FIG. 4. RNase protection assay (RPA), semiquantitative 5* RACE, and the 5* ends of preC and C transcripts of HBV DNA dimer. (A) Schema of
RPA and anchored 5* RACE. (B) The bands for the common region of preS-S, X, and preC-C RNA have slightly different intensities, whereas those
for the core mRNA differ. The same result was obtained using total RNA. (C) pTKGH was cotransfected with each CAT plasmid and RNA was
obtained from the culture dish producing the same amount of hGH. The RACE products were electrophoresed in 5% agarose gel and visualized
with ethidium bromide. The 140- and 100-bp bands correspond with preC and C transcripts, respectively. (D) Each 5* end of preC and C transcripts
is represented by a solid circle. The arrows show the created mutation. Start codons for the preC, DR1, as well as the pregenome encapsidation
signal (e) (Junker-Niepmann et al., 1990) are indicated. RACE products were digested with BamHI and EcoRI, electrophoresed in 5% agarose gel,
and the bands with sizes between 70 and 140 bp were excised and ligated with plasmid vectors. Seven or eight and four clones for preC and C
transcriptions, respectively, were picked up and the nucleotide sequences were determined.
transcription of the double mutant in our culture system. lated that abortion of HBeAg translation might lead to
severe hepatitis. In this study, we demonstrated an addi-Also, the double mutation reduced the amount of preC
mRNA and simultaneously increased the C mRNA. tional mechanism whereby the mutated overlapping preC
and C promoter regions directly alter their own activities.Therefore, the nucleotide changes might have altered
the affinity of TATA-binding protein for the second AT- This promoter mutation-dependent down-expression of
HBeAg might enable the mutants to replicate more easilyrich region (Chen et al., 1995) and reduced the preC
promoter activity. This hypothesis is supported by the than the partially suppressed wt (Lamberts et al., 1993),
and the mutation-dependent up-regulation of C expres-finding that A1762T was sufficient for the double-mutant
phenotype. The down-regulation of preC promoter activ- sion might promote this replication.
The low level production of HBeAg and HBsAg in ourity might have released the downstream C promoter from
occlusion by preC transcription. study might explain HBeAg-negative persistence in
which the circulating HBV titers are low, whereas theThe HBeAg titer from cells transfected with the
G1764A-mutation was the same as with wt (Table 2). enhanced replication and HBcAg production are compat-
ible with severe hepatitis in primary infection. Epidemio-Therefore, it seems unlikely that this mutation would be
selected in individuals who are seropositive for anti-HBe. logical studies of carrier patients (Alter et al., 1976; Okada
et al., 1976) and experimentally infected chimpanzeesThe G1764A-mutant might exist as an HBeAg-positive
wt. The A1762T mutation was essential and sufficient to (Shikata et al., 1977) have demonstrated that the pres-
ence of anti-HBe in individuals is closely associated withelicit the mutant phenotype demonstrated by the double
mutant (Table 2, Fig. 6). Thus, it is still unclear why the decreased copy numbers of the circulating viral genome
and low serum infectivity. To account for the high-repli-two-point mutation, but not one-point A1762T-mutation,
was selected in vivo. cator phenotype of mutant HBV in our culture system, a
low circulating virus titer in vivo would appear to be cre-Lamberts et al. (1993) observed that preC expression
acts to inhibit HBV replication in HepG2 cells and specu- ated by a subtle balance between viral replication and
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FIG. 5. Basal activities of mutated preC-C promoters determined by CAT-ELISA and 5* RACE 6 and 3 days, respectively, after transfection of
HepG2 cells with CAT constructs. (A) Structures of CAT-plasmids harboring the preC-C promoter fragment. HBV DNA fragments are represented
by thick lines, the original CAT plasmid DNA by horizontal dashed lines, open reading frames by boxes, transcriptional initiation sites of preC and
C mRNAs of p2WAG by large arrows, and 5* UTR of the preC transcripts by small arrows. (B) CAT-ELISA titers of cells transfected with the p.d5*CAT
series, representing the preC promoter activity. The mutation of pTA.d5*CAT is the same as that of p2WTA. (C) p.79.CAT series, representing the
C promoter activity. pTKGH was cotransfected as an internal control for transfection efficiency, and A492 minus the background (BKG) of the CAT-
ELISA was divided by A492 minus the BKG of hGH-ELISA and represented by arbitrary units. The average and 1 SD of the resulting units of triplicate
transfection are shown by the column and error bars, respectively. (D) 5* anchored RACE of total RNA isolated from cells transfected with p.79.CAT
series. pTKGH was cotransfected with each CAT plasmid and RNA was obtained from the culture dish producing the same amount of hGH. Ten
microliters of the PCR mixture of each pAG.79.CAT, pAA.79.CAT, and pTG.79.CAT and 15 ml of pTA.79.CAT were electrophoresed in 5% agarose
gel and visualized with ethidium bromide.
immunocompetition, rather than the low-replicating na- lak et al., 1995). The major T-cell targets are cells pre-
senting HBcAg peptides rather than HBsAg (Cerny et al.,ture of these mutants. Nevertheless, HBV carriers with
preC-C promoter mutations who are negative for both 1994; Sylvan et al., 1987; Milich and McLachlan, 1988;
Inoue et al., 1989). Thus, enrichment of the HBcAg supplyHBeAg and anti-HBe do occasionally exist (Okamoto et
al., 1994; Moriyama et al., 1994). They are asymptomatic may lead to severe hepatitis. The original hosts of fulmi-
nant infections, who have transmitted the preC ORF mu-and their circulating virus DNA titers are low. Thus, these
persistent infections cannot be clearly explained solely tants to the affected patients, have been reported to be
healthy HBV carriers (Fagan et al., 1986; Kojima et al.,in terms of the phenomenon we observed in vitro.
Common HBVs are noncytopathic viruses (Hoofnagle 1991). Therefore, HBeAg-negative viruses including both
preC ORF and/or preC-C promoter mutations should beet al., 1987) and the hepatocyte injury itself is caused by
the CTL responses against the infected cells (reviewed closely associated with each counterpart disease status.
One hypothesis is that the HBeAg-negative high HBcAg-by Cerny et al., 1994), possibly along with ADCC (Micha-
TABLE 2
HBV Antigen Titers in Cell Extracts and Culture Medium of HepG2 Cells Transfected with HBV Genome with the Double Mutation and Its
Singly Substituted Revertants
hGH (medium) HBsAg (medium) HBcAg (cell) HBeAg (medium)
p2WAG 1234a 1412a (75 { 7)b 331a (151 { 22) 1236a (270 { 18)
p2WTG 1032 868 (52 { 5) 834 (382 { 74) 626 (151 { 9)
p2WAA 1276 770 (34 { 5) 381 (160 { 6) 1618 (348 { 17)
p2WTA 1352 1021 (46 { 5) 949 (308 { 34) 574 (98 { 4)
Mock 78 38 21 10
a The average light absorbance (A492 1 1000) in ELISA of triplicate cultures.
b Light absorbance for each antigen was converted to the absolute unit using the standard curve, divided by the absolute unit of each hGH, and
the average and 1 SD of resulting triplicate relative units were represented in parenthesis.
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